Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.06 USD
-0.02 (-1.85%)
Updated Aug 1, 2024 04:00 PM ET
After-Market: $1.05 -0.01 (-0.94%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Gain Therapeutics, Inc. (GANX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.60 | $10.00 | $5.00 | 603.70% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for Gain Therapeutics, Inc. comes to $7.60. The forecasts range from a low of $5.00 to a high of $10.00. The average price target represents an increase of 603.7% from the last closing price of $1.08.
Analyst Price Targets (5 )
Broker Rating
Gain Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, five are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/GANX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/7/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
7/2/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
3/1/2024 | Chardan Capital Markets | Keay T Nakae | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 5 |
Average Target Price | $7.60 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 253 |
Current Quarter EPS Est: | -0.31 |